Quote | Profound Medical Corp. (NYSE:PROF)
Last: | $ |
---|---|
Change Percent: | -6.96% |
Open: | $17.40 |
Close: | $16.18 |
High: | $17.40 |
Low: | $15.97 |
Volume: | 161,321 |
Last Trade Date Time: | 02/12/2020 04:43:44 pm |
News | Profound Medical Corp. (NYSE:PROF)
2024-03-07 23:35:04 ET Profound Medical Corp. (PROF) Q4 2023 Earnings Conference Call March 07, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer Rashed Dewan – Chief Financial Off...
2024-03-07 17:14:10 ET More on Profound Medical Profound Medical lays out Q4 and FY 2024 preliminary numbers Profound Medical sells 2.67M shares at $7.50 in public offering Seeking Alpha’s Quant Rating on Profound Medical Historical earnings data for P...
Message Board Posts | Profound Medical Corp. (NYSE:PROF)
Subject | By | Source | When |
---|---|---|---|
After the presentation of four studies presented at | chocolate man | investorshub | 05/01/2023 9:11:29 PM |
My bad, i meant to say May 10th. | chocolate man | investorshub | 04/27/2023 4:20:16 PM |
The conf call is May 10? | hayfarmer | investorshub | 04/27/2023 3:56:27 PM |
I shoud have added that once again he | chocolate man | investorshub | 04/26/2023 3:57:54 PM |
I just listened to the Bloom Burton Healthcare | chocolate man | investorshub | 04/26/2023 2:34:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Profound Medical Corp. Company Name:
PROF Stock Symbol:
NYSE Market:
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...
TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, t...